NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $1.65 -0.15 (-8.33%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About ProKidney Stock (NASDAQ:PROK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProKidney alerts:Sign Up Key Stats Today's Range$1.62▼$1.8150-Day Range$1.55▼$2.4652-Week Range$1.18▼$4.44Volume329,693 shsAverage Volume445,666 shsMarket Capitalization$477.96 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company OverviewProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW ProKidney Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScorePROK MarketRank™: ProKidney scored higher than 52% of companies evaluated by MarketBeat, and ranked 587th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingProKidney has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageProKidney has only been the subject of 3 research reports in the past 90 days.Read more about ProKidney's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProKidney are expected to grow in the coming year, from ($0.54) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ProKidney's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.64% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently decreased by 3.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.64% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently decreased by 3.72%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.67 News SentimentProKidney has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ProKidney this week, compared to 2 articles on an average week.Search Interest2 people have searched for PROK on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,030.00 in company stock.Percentage Held by Insiders41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Stock News HeadlinesProKidney no longer coming to Greensboro, Chamber of Commerce confirmsNovember 21 at 5:09 AM | msn.comProKidney: Manufacturing expansion moving to W-S instead of GreensboroNovember 21 at 5:09 AM | bizjournals.comTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 21, 2024 | Colonial Metals (Ad)ProKidney lists Greensboro property for sale, leaving future in city uncertainNovember 19 at 7:03 AM | msn.comFuture of development project promising hundreds of job now uncertainNovember 19 at 2:02 AM | msn.comProKidney lists building where it planned $458M investment for saleNovember 18 at 9:01 PM | bizjournals.comPharma company to expand Broward headquartersNovember 15, 2024 | bizjournals.comProKidney’s Progress in FDA Approval and Financial HealthNovember 13, 2024 | markets.businessinsider.comSee More Headlines PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $1.78 at the beginning of 2024. Since then, PROK shares have decreased by 7.3% and is now trading at $1.65. View the best growth stocks for 2024 here. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Who are ProKidney's major shareholders? ProKidney's top institutional shareholders include Suvretta Capital Management LLC (4.26%), Geode Capital Management LLC (0.76%), State Street Corp (0.49%) and Charles Schwab Investment Management Inc. (0.26%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ProKidney own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA). Company Calendar Last Earnings11/12/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+172.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,470,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-10.24% Debt Debt-to-Equity RatioN/A Current Ratio17.08 Quick Ratio17.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.84) per share Price / Book-0.34Miscellaneous Outstanding Shares289,675,000Free Float169,489,000Market Cap$477.96 million OptionableOptionable Beta1.11 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:PROK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.